12/5/2014 | IGLM | Merck’s Schering-Plough redeems all $1 billion 6% notes due 2017
|
11/5/2009 | IG | S&P affirms Merck, lifts Schering-Plough
|
11/5/2009 | IG | Moody's affirms Merck, ups Schering-Plough
|
11/4/2009 | IG | Fitch cuts Merck, ups Schering-Plough
|
11/3/2009 | CV | Market Commentary: Ford edges up in the gray; Vornado exchange lifts REIT names; Schering-Plough takeout kicks in
|
10/29/2009 | SS | Merck, Schering-Plough merger granted additional regulatory approvals
|
10/23/2009 | SS | Merck, Schering-Plough merger expected to close in fourth quarter
|
9/14/2009 | SS | Market Commentary: Merck deal targeted for November close; Sprint stock up on bid rumors; Patheon snubs JLL
|
8/7/2009 | SS | Merck, Schering-Plough shareholders OK proposed stock-and-cash deal
|
8/7/2009 | SS | Market Commentary: Merck awaits end of reviews; IPC buyout may hinge on weather; FTC clears Watson Wyatt merger
|
8/6/2009 | SS | Market Commentary: Canadian Hydro urges against offer; Terra bid clears review; Schering to air deal vote
|
6/25/2009 | SS | Merck, Schering-Plough shareholders to decide merger on Aug. 7
|
6/22/2009 | SS | Market Commentary: Regulators eye Merck, Fidelity; Anglo American may be ripe for pact; Tower needs investor OK
|
6/16/2009 | SS | Market Commentary: Analyst: Sell Data Domain equity now; Merck, Schering meetings set; GM inks deal to sell Saab
|
5/28/2009 | SS | Johnson & Johnson tries to cancel distribution agreement with Schering
|
3/18/2009 | SS | Market Commentary: Sun Microsystems stock surges; NRG takes legal action; J&J might challenge Schering-Plough merger
|
3/17/2009 | SS | Market Commentary: Wyeth shares play catch-up to Pfizer bid; Exelon, NRG spar; Merck, Schering-Plough timing eyed
|
3/13/2009 | IG | Merck, Schering-Plough plan multi-tranche bond offering to pay down loans
|
3/11/2009 | SS | Market Commentary: Johnson & Johnson a thorn in Merck deal; Nobel Learning gets cheap bid; sale likely for Charlotte Russe
|
3/10/2009 | SS | Market Commentary: Merck merger hinges on regulatory OKs; Rohm gains from Dow's tardiness; United Tech on the hunt
|
3/9/2009 | CVIG | Moody's may lift Schering-Plough
|
3/9/2009 | CVIG | Fitch: Schering-Plough to benefit
|
3/9/2009 | SS | Merck to buy Schering-Plough for $41.1 billion in cash, stock
|
3/9/2009 | SS | Market Commentary: Merck plows over Schering-Plough; Dow, Rohm & Haas settle; Genentech wants more from Roche
|
3/9/2009 | CV | Market Commentary: Schering-Plough adds on merger news; energy names firmer; banks better; Johnson Controls to price
|
3/9/2009 | CVIG | S&P: Schering-Plough on positive watch
|
2/18/2009 | SP | Barclays to price 11% reverse convertibles linked to Schering-Plough
|
10/14/2008 | SP | RBC plans 13.5% reverse convertibles linked to Schering-Plough
|
9/26/2008 | SP | New Issue: Barclays prices $3 million 11.75% reverse convertibles linked to Schering-Plough
|
9/12/2008 | SP | Barclays to price 11.75% reverse convertibles linked to Schering-Plough
|
8/28/2008 | SP | New Issue: ABN Amro prices $0.35 million 15.5% reverse convertibles linked to Schering-Plough
|
8/27/2008 | IG | S&P: Schering-Plough view stable
|
8/14/2008 | IG | Fitch affirms Schering-Plough
|
8/8/2008 | SP | ABN Amro plans 15.5% knock-in notes linked to Schering-Plough
|
8/8/2008 | SP | Barclays to price 11.1% reverse convertibles linked to Schering-Plough
|
7/30/2008 | SP | New Issue: ABN Amro prices $0.1 million 10.1% reverse convertibles linked to Schering-Plough
|
7/30/2008 | SP | New Issue: Barclays prices $1.5 million 10.5% reverse convertibles linked to Schering-Plough
|
7/11/2008 | SP | Barclays to price 10.5% reverse convertibles linked to Schering-Plough
|
7/9/2008 | SP | ABN Amro plans 10.1% knock-in notes linked to Schering-Plough
|
7/7/2008 | SP | New Issue: Barclays prices $5 million 10% reverse convertibles linked to Schering-Plough
|
6/27/2008 | SP | New Issue: ABN Amro prices $2 million 10.75% reverse convertibles linked to Schering-Plough
|
6/27/2008 | SP | New Issue: ABN Amro prices $0.9 million 10% reverse convertibles linked to Schering-Plough
|
6/27/2008 | SP | New Issue: JPMorgan prices $68,000 10% reverse exchangeables linked to Schering-Plough
|
6/26/2008 | SP | Barclays to price 10% reverse convertibles linked to Schering-Plough
|
6/13/2008 | SP | New Issue: Barclays prices $4 million 15.25% reverse convertibles linked to Schering-Plough
|
6/11/2008 | SP | ABN Amro to price 10.75% reverse exchangeables linked to Schering-Plough
|
6/11/2008 | SP | Barclays to price 10.75% reverse convertibles linked to Schering-Plough
|
6/10/2008 | SP | JPMorgan to price 10% reverse exchangeables linked to Schering-Plough
|
6/6/2008 | SP | ABN Amro plans 10% knock-in notes linked to Schering-Plough
|
5/30/2008 | SP | New Issue: ABN Amro prices $0.5 million 13.8% reverse convertibles linked to Schering-Plough
|
5/29/2008 | SP | New Issue: JPMorgan prices $485,000 10.75% reverse exchangeables linked to Schering-Plough
|
5/29/2008 | SP | New Issue: Barclays prices $6 million 11.5% reverse convertibles linked to Schering-Plough
|
5/9/2008 | SP | Barclays to price 11.5% reverse convertibles linked to Schering-Plough
|
5/7/2008 | SP | ABN Amro plans 13.8% knock-in notes linked to Schering-Plough
|
5/6/2008 | SP | JPMorgan to price 10.75% reverse exchangeables linked to Schering-Plough
|
4/30/2008 | SP | New Issue: ABN Amro prices $1.7 million 15.2% reverse convertibles linked to Schering-Plough
|
4/29/2008 | SP | New Issue: JPMorgan prices $765,000 11% reverse exchangeables linked to Schering-Plough
|
4/8/2008 | SP | Barclays to price 14.5% reverse convertibles linked to Schering-Plough
|
4/7/2008 | SP | ABN Amro plans 15.2% reverse exchangeables linked to Schering-Plough
|
4/7/2008 | SP | JPMorgan to price 11% reverse exchangeables linked to Schering-Plough
|
4/3/2008 | CV | Market Commentary: Alpha Natural, Peabody higher on coal merger news; Intel, AMD, Micron firmer
|
4/2/2008 | CVIG | Fitch may cut Schering-Plough
|
4/1/2008 | CVIG | Moody's affirms Schering-Plough
|
3/31/2008 | CV | Market Commentary: Convertibles mixed in thin volume; Schering-Plough falls, Bank of America firmer; Merrill trades; Lehman to price
|
3/28/2008 | SP | New Issue: ABN Amro prices $1 million 10.4% reverse convertibles linked to Schering-Plough
|
3/28/2008 | SP | New Issue: Barclays prices $4 million 11% reverse convertibles linked to Schering-Plough
|
3/13/2008 | SP | New Issue: Lehman prices $1.9 million 13% reverse exchangeables linked to Schering-Plough
|
3/10/2008 | SP | Barclays to price 11% reverse convertibles linked to Schering-Plough
|
3/6/2008 | SP | ABN Amro to price 10.4% reverse exchangeables linked to Schering-Plough
|
3/6/2008 | SP | Lehman to issue 13% reverse exchangeables linked to Schering-Plough
|
2/28/2008 | SP | New Issue: Barclays prices $7 million 11% reverse convertibles linked to Schering-Plough
|
2/28/2008 | SP | New Issue: JPMorgan prices $436,000 13% reverse exchangeables linked to Schering-Plough
|
2/28/2008 | SP | Barclays to price 10% reverse convertibles linked to Schering-Plough
|
2/19/2008 | SP | Wachovia to price 12.5%-13.5% enhanced yield securities linked to Schering-Plough for Eksportfinans
|
2/12/2008 | CV | Market Commentary: Flotek, GMX Resources price deals cheap; Vertex coming next; Financials mixed on mortgage deal
|
2/11/2008 | SP | Barclays to price 11% reverse convertibles linked to Schering-Plough
|
2/11/2008 | SP | JPMorgan to price 13% reverse exchangeables linked to Schering-Plough
|
2/11/2008 | CV | Market Commentary: Yahoo! up after rejecting Microsoft; Flotek, Vertex Pharma bringing deals; GM, Schering-Plough earnings ahead
|
2/6/2008 | SP | Fortis plans 16.3% reverse convertibles linked to Schering-Plough
|
2/4/2008 | SP | SG Structured Products to price 19% Tempo ReConvs linked to Schering-Plough
|
1/30/2008 | SP | New Issue: Barclays prices $5 million 10.25% reverse convertibles linked to Schering-Plough
|
1/29/2008 | SP | New Issue: UBS prices $5.79 million 12.2% yield optimization notes linked to Schering-Plough
|
1/16/2008 | CVIG | S&P: Schering-Plough unaffected
|
1/14/2008 | CV | Market Commentary: Pioneer bringing new convertibles; doubts plague Countrywide; Schering-Plough down on drug test
|
1/14/2008 | SP | SG Structured Products to price 11.6% ReConvs linked to Schering-Plough
|
1/10/2008 | SP | Barclays to price 10.25% reverse convertibles linked to Schering-Plough
|
1/10/2008 | SP | UBS to price 8.75%-10% yield optimization notes linked to Schering-Plough
|
12/21/2007 | CV | Market Commentary: Washington Mutual pummeled on federal inquiry; Itron gets the gift of upgrade; ADC moves up on second day
|
12/12/2007 | CV | Market Commentary: WaMu takes wild ride; A&P, Network Equipment, Hecla Mining on tap; Countrywide down again
|
11/19/2007 | SS | Market Commentary: Celgene, Pharmion to merge, sending shares of Pharmion up; Quanex stock spikes on merger, spinoff
|
11/19/2007 | SS | Schering-Plough expands into two Rx franchises with acquisition of Organon
|
11/19/2007 | SP | Fortis plans 10.2% reverse convertibles linked to Schering-Plough
|
11/16/2007 | SS | Market Commentary: Coley zooms on Pfizer buyout plan; Schering-Plough climbs; AMD down after Mubadala stock purchase
|
11/16/2007 | SS | Schering-Plough's acquisition of Organon approved by FTC
|
10/22/2007 | IG | Market Commentary: Soft start deters news deals; financials weak in trading
|
10/11/2007 | SS | Market Commentary: Schering-Plough dips but gets European go-ahead to buy Organon; Sallie Mae up as other investors circle
|
9/26/2007 | CVIG | S&P rates Schering-Plough debt A-
|
9/26/2007 | CVIG | Fitch rates Schering-Plough debt BBB+
|
9/26/2007 | CVIG | Moody's rates Schering-Plough notes Baa1
|
9/12/2007 | IG | Market Commentary: Schering-Plough, American General, DCP Midstream, Hasbro, Alabama Power, KfW bring new deals
|
9/12/2007 | IG | New Issue: Schering-Plough prices upsized $2 billion of senior notes in two tranches
|
9/12/2007 | CVIG | S&P rates Schering-Plough debt A-
|
9/12/2007 | CVIG | Fitch rates Schering-Plough debt BBB+
|
9/11/2007 | IG | Moody's confirms Schering-Plough
|
9/11/2007 | IG | Fitch affirms Schering-Plough
|
9/5/2007 | SP | Fortis Bank plans 8.75% knock-in reverse convertibles linked to Schering-Plough
|
8/30/2007 | CV | Market Commentary: Thornburg launches preferreds; Schering-Plough, other biotechs active; Sirius starts truckin'
|
8/15/2007 | CVIG | S&P rates Schering-Plough convertibles BBB
|
8/14/2007 | CV | Market Commentary: Schering-Plough rallies; Chesapeake Energy, Nuance active; Anixter, EMC drop; VeriSign on the way
|
8/14/2007 | CVIG | Fitch gives Schering-Plough convertible preferreds BBB-
|
8/14/2007 | IG | Moody's assigns Schering-Plough convertibles Baa3
|
8/10/2007 | CV | New Issue: Schering-Plough prices $2.5 billion mandatory convertible preferred stock at 6%, up 22.5%
|
8/10/2007 | CV | Market Commentary: Schering-Plough makes debut; Countrywide battered by misunderstanding; market has 'choppy' Friday
|
8/9/2007 | CV | Schering-Plough prices $2.5 billion convertibles at 6%, up 22.5%
|
8/7/2007 | CV | Market Commentary: Luminent slides; Countrywide rallies; CapitalSource stalls; Schering-Plough talk welcomed
|
8/3/2007 | CV | Fitch rates Schering-Plough convertible BBB-
|
8/2/2007 | CV | Schering-Plough files automatic shelf registration
|
8/2/2007 | CV | Schering-Plough launches $2.5 billion of mandatory convertible preferred stock due 2010
|
8/2/2007 | CV | Market Commentary: Schering-Plough set to launch; Horizon fails to excite; Beazer Homes, CapitalSource rebound
|
7/12/2007 | CV | S&P keeps Schering-Plough on watch
|
3/13/2007 | CV | Fitch downgrades Schering-Plough
|
3/12/2007 | CV | Moody's may downgrade Schering-Plough
|
3/12/2007 | SS | Market Commentary: New Century demise imminent; Ocwen off; Gateway, Openwave higher; Tribune trips; Cortex rises
|
3/12/2007 | CV | S&P: Schering-Plough on watch
|
12/13/2006 | CV | Moody's ups Schering-Plough view to positive
|
10/23/2006 | BT | Schering-Plough rated at underperform by Bear Stearns
|
10/20/2006 | BT | Schering-Plough to invest in pipeline advancements; says quarterly net sales, income up
|
9/28/2006 | BT | Pharmacopeia extends agreement with Schering-Plough
|
9/18/2006 | BT | Schering-Plough: FDA approves Noxafil for infections
|
8/29/2006 | BT | Schering-Plough unit pleads guilty to one count, settles investigation for $435 million
|
8/29/2006 | BTCV | S&P: Schering-Plough unchanged
|
8/29/2006 | BTCV | Fitch: Schering-Plough unaffected
|
8/29/2006 | BT | Market Commentary: Teva lower; Endo, Penwest up; StemCells gains 7%; Nastech higher; Hemispherx rises 11%
|
8/17/2006 | BT | Schering-Plough study shows vicriviroc decreases viral load in treatment-experienced HIV patients
|
8/17/2006 | BT | Xenogen, Schering-Plough form target validation collaboration
|
8/14/2006 | BT | Schering-Plough, Novartis to develop once-daily inhaled combination therapy for asthma, COPD
|
7/24/2006 | BT | Schering-Plough second-quarter net income rises to $237 million, or 16 cents per share
|
6/21/2006 | BT | Schering-Plough expands Latin American presence, restructures operations in Brazil
|
6/19/2006 | BT | Merck/Schering-Plough: Vytorin lowers 'bad' cholesterol better than Crestor
|
6/19/2006 | BTCV | Fitch lifts Schering-Plough view to stable
|
6/12/2006 | BT | Merck/Schering-Plough: Vytorin superior to Lipitor in diabetic patients
|
6/9/2006 | BT | FDA approves new indication for Merck/Schering-Plough's cholesterol-lowering drug
|
6/1/2006 | BT | Schering-Plough lays off 1,100 employees, closes Puerto Rico facility
|
6/1/2006 | BT | Market Commentary: Targeted Genetics' stock jumps 18% on promising data; Endologix raises $20.13 million from stock sale
|
5/23/2006 | BT | Schering-Plough starts new hepatitis C study in liver transplant patients
|
5/18/2006 | BT | Moody's lifts Schering-Plough outlook to stable
|
5/17/2006 | BT | MorphoSys licenses HuCal Gold technology to Schering-Plough
|
4/26/2006 | BT | Schering-Plough: long-term efficacy data leads to EU label change for Intron A for hepatitis C
|
4/20/2006 | BT | Schering-Plough expands phase 2 study of SCH 503034 for hepatitis C
|
4/20/2006 | BT | Schering-Plough 1Q net income rises to $350 million, reports continued sales growth
|
4/19/2006 | BT | Schering-Plough's antiplatelet agent SCH 530348 gets fast track designation from FDA
|
4/17/2006 | BT | Pharmacopeia, Schering-Plough identify novel therapeutic candidate for metabolic disease
|
4/7/2006 | BT | Schering-Plough says Avelox monotherapy as effective as high-dose combination therapy
|
3/24/2006 | BTCV | S&P lifts Schering-Plough view to stable
|
3/21/2006 | BT | Bear Stearns rates Schering Plough at underperform
|
3/20/2006 | BT | Schering-Plough, PTC to collaborate on preclinical hepatitis C compounds
|
3/13/2006 | BT | Merck/Schering-Plough says Vytorin lowers 'bad' cholesterol more than Zocor
|
3/10/2006 | BT | Market Commentary: Insmed, Corautus off on deals; NPS Pharma gains, dives on FDA; CV Therapeutics higher; Kos up
|
3/9/2006 | BT | Centocor, Schering Plough: Remicade approved in Europe for ulcerative colitis
|
3/7/2006 | BT | Schering-Plough at underperform by Bear Stearns
|
3/7/2006 | BT | Schering-Plough restructures European, Latin American and Asia-Pacific regions
|
3/3/2006 | BT | Malignancies found in Schering-Plough phase 2 trial of vicriviroc for HIV
|
2/23/2006 | BT | Bear Stearns cuts Schering-Plough to underperform
|
2/22/2006 | BT | Schering-Plough Noxafil antifungal NDA granted priority review by FDA
|
2/13/2006 | BT | Schering-Plough's New Drug Application for antibiotic garenoxacin accepted for FDA review
|
2/10/2006 | BT | Schering-Plough says vicriviroc well tolerated; dosing, background regimen need further study
|
2/2/2006 | BT | Schering-Plough's Temodal approved in Canada for newly diagnosed brain cancer
|
2/1/2006 | BT | Schering-Plough wins FDA approval for Clarinex-D 12 hour
|
1/31/2006 | BT | Schering-Plough rated peer perform by Bear Stearns
|
1/30/2006 | BT | E.U. committee recommends approval of Remicade for active ulcerative colitis
|
1/30/2006 | BT | Schering-Plough hepatitis C protease inhibitor in phase 2 trial, approved for FDA fast track
|
1/24/2006 | BT | Schering-Plough: study shows favorable results of using Avelox for pneumonia
|
1/13/2006 | BT | Schering-Plough begins phase 3 study of Peg-Intron in patients coinfected with hepatitis C, HIV
|
12/22/2005 | BT | Schering-Plough receives Japanese approval for additional Peg-Intron indication
|
12/13/2005 | BT | Schering-Plough's Nasonex spray shrinks nasal polyps, study says
|
12/1/2005 | BT | Schering-Plough cancels trials on respiratory indications for a Pharmacopeia-collaborated drug
|
11/16/2005 | BT | Centocor, Schering-Plough arthritis drug golimumab more effective than placebo, phase 2 study says
|
11/14/2005 | BT | Schering-Plough's Integrilin improves artery blood flow in ER heart-attack patients
|
11/14/2005 | BT | Schering Plough: PEG-Intron/Rebetol combination shows high response rates in hepatitis C patients
|
11/14/2005 | BT | Schering-Plough's SCH 503034 lowers viral load in hepatitis C patients, study shows
|
10/31/2005 | BT | Schering-Plough's Temodal improves glioblastoma multiforme survival
|
10/27/2005 | BT | Schering-Plough's Noxafil approved in European Union for treatment of invasive fungal infections
|
10/25/2005 | BT | Schering-Plough study finds Noxafil better at treating fungal infection than fluconazole
|
10/24/2005 | BT | Market Commentary: Roche, Gilead gain on flu talks; niche flu names higher as well; Schering, Wyeth, Pfizer watched
|
7/6/2005 | CV | Market Commentary: Cooper Cameron, Halliburton rise as oil prices surge; Schering-Plough eases, but LSI gains
|
6/21/2005 | BTCV | Fitch affirms Schering-Plough
|
4/15/2005 | CV | Market Commentary: GM, Ford selling accelerates; El Paso, Calpine, NRG plunge; Ivax, Teva lose; Lucent, Tyco unwound
|
2/28/2005 | CV | Market Commentary: Elan hurt, Biogen stable; Teva up, Schering slips; King trips; Yellow skids; Manpower lower; Saks off
|
1/27/2005 | CV | Merrill removes Schering-Plough mandatory from convertible portfolio on equity downgrade to neutral
|
1/27/2005 | CV | Market Commentary: Open Solutions higher in gray market; Rambus quiet, last seen at 98.5 offer; Rite Aid edges up
|
1/14/2005 | CV | Market Commentary: CNet gains 4 points; Collegiate Pacific higher; UnumProvident up; Wyeth rises, Schering drops
|
9/30/2004 | CV | Market Commentary: Ford, GM convertibles see little traffic ahead of Sept sales; Schering-Plough shoots up
|
9/22/2004 | CV | New Issue: ABN Amro sells $2 million 9% reverse exchangeables linked to Schering-Plough
|
8/6/2004 | CV | Market Commentary: SFBC hits high mark of 104.125, while other new paper off a tad; GM, Ford pressured; Delta dives
|
8/5/2004 | CV | Market Commentary: SFBC bid up 1.25 points in gray; Goodyear earnings push up bonds; Schering-Plough, new issues gain
|
8/5/2004 | CV | New Issue: Schering-Plough $1.25 billion mandatory at 6.0% dividend, up 24%
|
8/4/2004 | CV | S&P rates Schering-Plough convertibles
|
8/4/2004 | CV | Fitch rates Schering-Plough convertible
|
8/4/2004 | CV | Market Commentary: Schering-Plough bid up in gray; Henry Schein goes to 102.25; News Corp. off on BskyB news
|
8/4/2004 | CV | Schering-Plough $1.25 billion mandatory convertible talked at 6.0%-6.5%, up 20%-24%
|
10/10/2003 | CV | New Issue: ABN Amro sells $15 million 11% reverse exchangeables linked to Schering-Plough
|
5/20/2003 | CV | New Issue: Morgan Stanley prices $55.96 million 8% Sparqs exchangeable for Schering-Plough
|
7/26/2002 | CV | New Issue: Goldman Sachs prices $22.5 million 9% notes mandatorily exchangeable for Schering
|